GSK to Invest $30 Billion in US R&D and Manufacturing
Includes $1.2 billion in manufacturing facilities, AI, and advanced digital technologies, creating hundreds of highly skilled US jobs.
GlaxoSmithKline (GSK)
28.01.2025 • News
GSK and Oxford University Collaborate on Cancer Vaccines
GSK and the University of Oxford have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The program, in which GSK plans to invest up to £50 million over a minimum of three years, will conduct translational research, exploring precancer biology to generate key insights on how cancer develops in humans that could inform future development of cancer vaccines.
09.01.2025 • News
GSK May Acquire Cancer Specialist IDRx for $1 Billion
In a move to expand its oncology business, GSK is nearing a $1 billion deal to buy a US biotech developing a treatment for rare gastrointestinal tumors.
31.10.2024 • News
GSK Acquires Lupus Drug Candidate from Chimagen Biosciences
GlaxoSmithKline (GSK) agreed to acquire a clinical-stage drug from Chimagen Biosciences, a privately held Chinese biotechnology company. CMG1A46 is a dual CD19 and CD20-targeted T cell-engager (TCE), which GSK plans to develop and commercialize with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases.
29.10.2024 • News
GSK to Invest $800 Million in US Manufacturing Facility
British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.
30.07.2024 • News
GSK and Flagship Pioneering Collaborate on Novel Medicines and Vaccines
GSK and innovation company Flagship Pioneering have entered a collaboration to develop a portfolio of new medicines and vaccines, starting in respiratory and immunology. Flagship’s ecosystem comprises 40 bioplatform companies, including Moderna.
24.07.2024 • News
Touchlight and GSK Sign License Agreement for DNA Production
Touchlight, a UK-based custom development and manufacturing organization (CDMO) specializing in enzymatic DNA production, signed a license agreement with British drugmaker GSK which grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA (doggybone DNA) technology for the development and production of mRNA-based products.
10.01.2024 • News
GSK to Buy Respiratory Drug Developer Aiolos Bio
GSK has agreed to acquire biotech Aiolos Bio for a $1 billion upfront payment and up to $400 million for the achievement of certain milestones. Founded just last year, Aiolos is a San Francisco, USA and London, UK-based biopharmaceutical company that develops treatments for respiratory diseases.
11.10.2023 • News
GSK and Zhifei Co-Promote Shingles Vaccine in China
GSK has struck a deal with Chongqing Zhifei Biological Products to promote the British group's shingles vaccine, Shingrix, in China for an initial three-year period. Starting on Jan.1, 2024, Zhifei will have exclusive rights to import and distribute Shingrix in China through its service network of more than 30,000 vaccination points across the country.
Navigating Uncertainty in the Biopharma Market
Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.
27.04.2023 • News
European Drugmakers Slam EU Reform Proposals
European NGOs have welcomed the EU’s plans for an overhaul of pharmaceutical legislation – the first in two decades – presented this week in Brussels. The drugs industry, however, has expressed sharp criticism.
03.04.2023 • News
GSK Agrees Exclusive License for Novel Antifungal
GSK is set to gain exclusive rights to first-in-class oral antifungal Brexafemme (ibrexafungerp) for treating vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC) from US biotech Scynexis. The treatment is also currently undergoing Phase 3 clinical trials for invasive candidiasis (IS), a life-threatening fungal infection.
21.03.2023 • News
Global Pharma Reduces Marketing Staff in India
As part of what seems to be a general pattern of staff reductions in the pharmaceutical industry worldwide, a growing number of Western drugmakers are downsizing their sales and marketing presence in India.
20.02.2023 • News
GSK Prunes Ties with US Biotech Vir
GSK is pruning its cooperation with Vir Biotechnology, turning away from Covid-19 antibody and vaccine research projects while continuing to collaborate with the company on two pandemic assets and programs to treat other respiratory diseases.
01.02.2023 • News
CureVac Presents Positive Data from mRNA Trials
German biotech CureVac has released preliminary data from its ongoing cooperation with UK drugmaker GSK on a new class of “transformative medicines” based on messenger mRNA.
19.12.2022 • News
GSK and Wave Life Sciences Partner on Genetics
British pharma GSK has entered into a four-year collaboration with US clinical-stage genetic medicines company Wave Life Sciences to advance oligonucleotide therapeutics, including Wave’s preclinical RNA-editing program targeting alpha-1 antitrypsin deficiency (AATD), an inherited disorder that can cause lung and liver disease.
05.12.2022 • News
UK’s CPI Opens Medicines Manufacturing Innovation Center
The UK’s Center for Process Innovation (CPI) opened its Medicines Manufacturing Innovation Center in Glasgow on Nov. 30, with the aim of accelerating new technologies in the pharma industry.
11.11.2022 • News
EU Approves Sanofi/GSK Covid Booster
After several delays and restarts and a lengthy review by the European Medicines Agency (EMA), the Covid-19 vaccine called VidPrevtyn Beta developed by the French-British partnership of Sanofi and GSK has been greenlighted by the European Commission.
08.11.2022 • News
Pharma CEOs Take Action on Climate Change
The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.
30.09.2022 • News
GSK Names Julie Brown as First Female CFO
From next year, GSK’s top management will be led by a double female team, a pioneering move for the global pharmaceutical industry. The UK drugs giant this week announced the appointment of Julie Brown, the first woman to be its chief financial officer.
30.09.2022 • News
GSK Names Julie Brown as first female CFO
From next year, GSK’s top management will be led by a double female team, a pioneering move for the global pharmaceutical industry. The UK drugs giant this week announced the appointment of Julie Brown, the first woman to be its chief financial officer.
27.09.2022 • News
Unilever Chief to Quit sooner after failed GSK Bid
British-multinational consumer products giant Unilever has announced that its chief executive, Alan Jope, will retire at the end of 2023. The potentially earlier than planned departure announcement had been anticipated.
23.08.2022 • News
CureVac and GSK launch Phase 1 for Covid Booster
CureVac and GSK have announced they are launching a Phase 1 clinical trial with their modified mRNA-based Covid 19 vaccine CV051, which would be recommended as a booster to protect against the omicron variant.
21.07.2022 • News
GSK’s Consumer Health Flotation Flags
The Jul.18 launch of GSK’s consumer healthcare spinoff Haleon on the London Stock Exchange – said to be the largest London listing in more than a decade – seems to have gone off more like a whimper than a bang.
27.06.2022 • News • Innovation
New Covid Shots Score Points against Omicron
Sanofi and GSK are touting their latecomer protein-based Covid-19 vaccine as a potential game changer in the fight against the Omicron variant.
07.06.2022 • News
FDA Greenlights GSK’s MMR Vaccine
The US Food and Drug Administration (FDA) has greenlit GSK’s Priorix-branded GSK’s mumps and rubella vaccine (MMR) for people 12 months and older. It is only the second such shot to be licensed for US distribution in more than 50 years. Merck & Co’s MMR-II vaccine was approved by the FDA for the pediatric application in 1971.
03.06.2022 • News
Pfizer to Quit GSK Consumer JV with Cash Windfall
Pfizer is set to start divesting its 32% stake in Haleon, the consumer health joint venture with GSK, when the British pharma completes the company’s spinoff and Haleon begins trading on the London Stock Exchange on July 18.
18.05.2022 • News
GSK Officially Changes Name – to GSK
Major UK pharmaceutical producer GlaxoSmithKline is slimming down not only by spinning off its consumer health business. It is also shedding excess verbiage by trimming its name to the three-letter acronym the company is known by, GSK.
25.04.2022 • News
GSK Union Threatens Strike over “unacceptable” Pay Offer
British drugs giant GlaxoSmithKline is facing what could be the first industrial action in its history. Some 86% of its employees organized in the trade union Unite at manufacturing sites across the UK voted last week to go on strike, rejecting a pay increase of 4%.
Where Science Meets Business
From its inception in 1881, SCI's principal objective has been to further the application of chemistry and related sciences into industry for the public benefit.
14.04.2022 • News
GSK to Buy Sierra Oncology for £1.5 Billion
British drugs giant GlaxoSmithKline (GSK) is buying US cancer treatment developer Sierra Oncology for £1.5 billion in a deal observers see as designed to fend off pressure from activist shareholder Elliott Management, which has been pushing the company to expand its pipeline.
12.04.2022 • News
Six Firms to Make Vaccines for German Emergency Supply
Germany’s economics ministry has budgeted up to €2.9 billion ($3.14 billion) to ensure sufficient supply of mostly mRNA-based Covid-19 vaccines to be able to deal with the ongoing pandemic and any future outbreaks up to 2029.
07.04.2022 • News
CDC and FDA Sideline Last Covid Antibody Treatment
The US Centers for Disease Control and the Food and Drug Administration have removed the IV antibody treatment sotrovimab made by GlaxoSmithKline (GSK) and Vir Biotechnology from the list of approved drug therapies for Covid-19.
29.03.2022 • News
WHO Rejects Medicago's Covid Vaccine
The Covid-19 vaccine Covifenz made by Canada’s Medicago, approved for use in the country in February, has been rejected for review by the World Health Organization (WHO) on grounds that the company is partly owned by tobacco company Philip Morris.
02.03.2022 • News
Health Canada Approves Medicago’s Covid Vaccine
Health Canada has approved the recombinant Covid-19 vaccine produced by Canadian biotech Medicago that uses the pandemic adjuvant made by British pharma giant GlaxoSmithKline. The shot marketed as Covifenz uses a plant-based virus-like particles technology to imitate the coronavirus’ spike protein.
Codexis
Sanofi S.A.
EvaluatePharma
Microinnova Engineering GmbH
Society of Chemical Industry (SCI)
GlobalData
KPMG
Cincinnati USA Reg. Chamber
Novartis International AG
Thomson Reuters
Oracle Germany
GlaxoSmithKline (GSK) plc
Merck & Co
Chemical Market Reporter
ISPE D/A/CH e.V.
Thermo Fisher Scientific
Novo Nordisk A/S
EDB Singapore